Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Introduction The use of applied modeling in dementia risk prediction, diagnosis, and prognostics will have substantial public health benefits, particularly as "deep phenotyping" cohorts with multi-omics health data become available. Methods This narrative review synthesizes understanding of applied models and digital health technologies, in terms of dementia risk prediction, diagnostic discrimination, prognosis, and progression. Machine learning approaches show evidence of improved predictive power compared to standard clinical risk scores in predicting dementia, and the potential to decompose large numbers of variables into relatively few critical predictors. Results This review focuses on key areas of emerging promise including: emphasis on easier, more transparent data sharing and cohort access; integration of high-throughput biomarker and electronic health record data into modeling; and progressing beyond the primary prediction of dementia to secondary outcomes, for example, treatment response and physical health. Discussion Such approaches will benefit also from improvements in remote data measurement, whether cognitive (e.g., online), or naturalistic (e.g., watch-based accelerometry).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lyall, D. M., Kormilitzin, A., Lancaster, C., Sousa, J., Petermann-Rocha, F., Buckley, C., et al. (2023). Artificial intelligence for dementia-Applied models and digital health. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13391

Vancouver

Lyall DM, Kormilitzin A, Lancaster C, Sousa J, Petermann-Rocha F, Buckley C, et al. Artificial intelligence for dementia-Applied models and digital health. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13391. PMID: 37496259.

BibTeX

@article{lyall2023-37496259,
  author  = {Lyall, D. M. and Kormilitzin, A. and Lancaster, C. and Sousa, J. and Petermann-Rocha, F. and Buckley, C. and Harshfield, E. L. and Iveson, M. H. and others},
  title   = {{Artificial intelligence for dementia-Applied models and digital health}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.13391},
  pmid    = {37496259},
  url     = {https://doi.org/10.1002/alz.13391}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This narrative review reports that machine learning approaches show improved predictive power compared to standard clinical risk scores in predicting dementia. It discusses prediction and digital health tools, not treatments or cures for Alzheimer's disease.

Study details

How this study scored 56/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 56 of 100.56 of 100 points earned44 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 68 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.6 citations a year over 5 year(s) since 2023
Impact for its field and year 4 / 6 Cited 12.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 14 other studies in this library
Still being cited 3 / 4 Cited 62 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Janice M. Ranson: h-index 26 (OpenAlex, whole career)
Institution's track record 3 / 3 Broad Institute: institution h-index 2,541 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 16 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37496259)
Free to read 2 / 2 Free to read
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 27.

Later studies that cite this one

14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Digital health tools

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Similar studies

More on Digital health tools

See all studies in Digital health tools →